With $75.1 million in cash and minimal competition, aTyr Pharma is well-positioned financially, making it a compelling ...

Tyr Pharma Inc (ATYR) reports robust financial health and significant progress in its pivotal phase three study for pulmonary ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...

No safety concerns identified by independent data and safety monitoring board (DSMB), which recommends continuation of study ...

Sarcoidosis is a rare systemic disease that afflicts an estimated 200,000 people in the U.S., more often people who are Black ...

Cardiac sarcoidosis (CS) was a complication in about 10% of pulmonary sarcoidosis (PS) cases, investigators reported in Respiratory Medicine. The retrospective study assessed the prevalence, incidence ...

The following is a summary of "Respiratory abnormalities in sarcoidosis: physiopathology and early diagnosis using ...

Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

SAN DIEGO - aTyr Pharma, Inc. (NASDAQ: ATYR) reported a narrower-than-expected fourth quarter loss on Wednesday, but shares fell 4.8% in after-hours trading as investors focused on the company’s cash ...

Considering taking supplements to treat sarcoidosis? Below is a list of common natural remedies used to treat or reduce the symptoms of sarcoidosis. Follow the links to read common uses ...